PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

ivabradine Side Effects

The reactions most often reported to the FDA for ivabradine (also sold as Corlanor), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

6,539
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2007 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of ivabradine come from 6,539 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 6,539 reports to the FDA Adverse Event Reporting System (FAERS) for ivabradine (Corlanor): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

6,539

Reports Mentioning Death

494

7.6% of reports — not proof the medicine caused the death

Hospitalizations

2,361

36.1% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DYSPNOEA
460
HYPOTENSION
413
DIZZINESS
350
CARDIAC FAILURE
324
FATIGUE
317
DRUG INTERACTION
308
NAUSEA
253
BRADYCARDIA
248
HEADACHE
231
CHEST PAIN
195
MALAISE
185
PALPITATIONS
174
ASTHENIA
162
SYNCOPE
156
DIARRHOEA
153
OEDEMA PERIPHERAL
152
DEATH
142
HEART RATE INCREASED
142

Who Reports Side Effects

Gender Distribution

Female 3,218 (58%)
Male 2,364 (42%)
Unknown 6

Age Distribution

0-17 116 (2%)
18-44 1,198 (26%)
45-64 1,578 (34%)
65-74 993 (21%)
75+ 791 (17%)

Reporting Trend by Year

2007 2025

Reactions in Death Reports

Top reactions reported in 494 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 142
CARDIAC FAILURE 63
HYPOTENSION 42
PNEUMONIA 37
DYSPNOEA 34
ACUTE KIDNEY INJURY 28
CARDIAC ARREST 28
MULTIPLE ORGAN DYSFUNCTION SYNDROME 22
PYREXIA 21
FALL 19
ARRHYTHMIA 18
SEPSIS 18
TOXICITY TO VARIOUS AGENTS 18
EJECTION FRACTION DECREASED 17
INTENTIONAL OVERDOSE 17
BEZOAR 16
FEBRILE NEUTROPENIA 16
PNEUMONIA ASPIRATION 16
CONDITION AGGRAVATED 15

Reactions in Hospitalization Reports

Top reactions in 2,361 reports where hospitalization was an outcome.

Reaction Reports
HYPOTENSION 257
DYSPNOEA 256
CARDIAC FAILURE 246
DRUG INTERACTION 167
BRADYCARDIA 132
DIZZINESS 131
ACUTE KIDNEY INJURY 123
FATIGUE 117
OEDEMA PERIPHERAL 112
NAUSEA 96
CHEST PAIN 91
PNEUMONIA 90
HEADACHE 89
SYNCOPE 89
ASTHENIA 85
PULMONARY OEDEMA 85
FALL 84
MALAISE 82

Compare ivabradine vs adenosine →

What the FAERS Data Reveals About ivabradine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 6,539 voluntary reports linked to ivabradine and its brand equivalents (Corlanor), spanning 2007 through 2025. Of those, 494 (7.6%) listed death as an outcome and 2,361 (36.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 45-64, with 1,578 reports in that bracket. The single most reported reaction is dyspnoea with 460 submissions, followed by hypotension and dizziness.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.